Should I buy or sell Enovis stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENOV shares. View ENOV analyst ratings or view top-rated stocks .

What is Enovis' stock price target for 2024?

8 brokers have issued 12 month price objectives for Enovis' shares. Their ENOV share price targets range from $70.00 to $82.00. On average, they anticipate the company's share price to reach $75.43 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price. View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts .

How have ENOV shares performed in 2024?

Enovis' stock was trading at $56.02 at the beginning of 2024. Since then, ENOV shares have increased by 1.4% and is now trading at $56.82. View the best growth stocks for 2024 here .

When is Enovis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ENOV earnings forecast .

How were Enovis' earnings last quarter?

Enovis Co. (NYSE:ENOV) released its quarterly earnings results on Thursday, February, 22nd. The company reported $0.79 EPS for the quarter, topping analysts' consensus estimates of $0.76 by $0.03. The firm had revenue of $455 million for the quarter, compared to analyst estimates of $444.34 million. Enovis had a negative net margin of 1.95% and a positive trailing twelve-month return on equity of 3.84%. The company's revenue for the quarter was up 11.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.72 earnings per share.

What ETFs hold Enovis' stock?

ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Dimensional US Small Cap Value ETF (DFSV) . iShares U.S. Medical Devices ETF (IHI) .

What guidance has Enovis issued on next quarter's earnings?

Enovis issued an update on its FY24 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of $2.50-$2.65 for the period, compared to the consensus earnings per share estimate of $2.70. The company issued revenue guidance of $2.05-$2.15 billion, compared to the consensus revenue estimate of $2.02 billion.

Who are Enovis' major shareholders?

Enovis' stock is owned by many different institutional and retail investors. Top institutional investors include Portman Square Capital LLP (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include A Clayton Perfall , Bradley J Tandy , Brady Shirley , Christopher M Hix , Daniel A Pryor , John Kleckner , Matthew L Trerotola , Patricia A Lang , Phillip Benjamin (Ben) Berry and Rajiv Vinnakota . View institutional ownership trends .

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NYSE:ENOV

Enovis (ENOV) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free ENOV Stock Alerts

$56.82

-1.73 (-2.95%)

(As of 04/15/2024 ET)

Compare

Today's Range: $56.49
▼
$58.82
50-Day Range: $56.82
▼
$63.80
52-Week Range: $43.04
▼
$66.14

Volume: 578,861 shs
Average Volume: 451,726 shs
Market Capitalization: $3.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $75.43

Get Enovis alerts:

Enovis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 32.8% Upside
$75.43 Price Target
Short Interest: Bearish
8.74% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 18.22%
From $2.58 to $3.05 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.54 out of 5 stars

Medical Sector

278th out of 929 stocks

Surgical Appliances & Supplies Industry

11th out of 18 stocks

4.5

Analyst's Opinion

Consensus Rating
Enovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Enovis has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
8.74% of the float of Enovis has been sold short.
Short Interest Ratio / Days to Cover
Enovis has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Enovis has recently increased by 4.35%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Enovis does not currently pay a dividend.
Dividend Growth
Enovis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENOV.

2.0

News and Social Media Coverage

News Sentiment
Enovis has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Enovis this week, compared to 4 articles on an average week.
MarketBeat Follows
Only 5 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enovis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.40% of the stock of Enovis is held by insiders.
Percentage Held by Institutions
98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Enovis are expected to grow by 18.22% in the coming year, from $2.58 to $3.05 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Enovis is -93.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enovis is -93.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enovis has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Enovis Stock (NYSE:ENOV)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

ENOV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENOV Stock News Headlines

April 12, 2024 | americanbankingnews.com

Enovis (NYSE:ENOV) Earns Buy Rating from Needham & Company LLC

April 9, 2024 | americanbankingnews.com

Enovis Co. (NYSE:ENOV) Receives Consensus Recommendation of "Buy" from Analysts

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

April 9, 2024 | americanbankingnews.com

Head to Head Analysis: Enovis (NYSE:ENOV) vs. LogicMark (NASDAQ:LGMK)

April 1, 2024 | msn.com

Enovis Corporation to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024 | msn.com

Don't expect pandemic backlog to fuel orthopedic sales, says Needham

March 28, 2024 | finance.yahoo.com

Enovis to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 17, 2024 | finance.yahoo.com

ENOV Dec 2024 60.000 put

April 16, 2024 | InvestorPlace (Ad)

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

March 17, 2024 | finance.yahoo.com

ENOV Mar 2024 60.000 put

March 16, 2024 | finance.yahoo.com

ENOV Jun 2024 50.000 put

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Enovis Amidst Strong Market Position and Strategic Growth Initiatives

February 25, 2024 | msn.com

Enovis Corporation Reports Strong 2023 Growth, Forecasts Positive 2024 Outlook

February 24, 2024 | msn.com

Enovis (ENOV) Price Target Increased by 6.10% to 76.70

February 23, 2024 | markets.businessinsider.com

Enovis Poised for Growth: Strong Q4 Performance and Optimistic 2024 Outlook Affirm Buy Rating

February 23, 2024 | finance.yahoo.com

Q4 2023 Enovis Corp Earnings Call

February 22, 2024 | msn.com

Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact

February 22, 2024 | finanznachrichten.de

Enovis Corporation: Enovis Announces Fourth Quarter and Full Year 2023 Results

February 22, 2024 | finance.yahoo.com

Enovis Announces Fourth Quarter and Full Year 2023 Results

February 22, 2024 | finance.yahoo.com

Enovis Corp (ENOV) Reports Solid Growth in Q4 and Full Year 2023 Earnings

February 22, 2024 | globenewswire.com

Enovis Announces Fourth Quarter and Full Year 2023 Results

February 21, 2024 | msn.com

Enovis Corporation Q4 2023 Earnings Preview

February 17, 2024 | finance.yahoo.com

ENOV Mar 2024 70.000 call

February 14, 2024 | msn.com

Enovis Corporation Unveils Pioneering Orthopedic Solutions at 2024 AAOS Annual Meeting

February 13, 2024 | msn.com

Stephens starts Enovis at overweight, cites "compelling" growth story

February 13, 2024 | markets.businessinsider.com

5 Analysts Have This To Say About Enovis

February 12, 2024 | stockhouse.com

Enovis(TM) to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting

See More Headlines

Receive ENOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Current Symbol: NYSE:ENOV
CUSIP: N/A
CIK: 1420800
Web: www.enovis.com
Phone: 302-252-9160
Fax: 301-323-9001
Employees: 6,550
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $75.43
High Stock Price Target: $82.00
Low Stock Price Target: $70.00
Potential Upside/Downside: +32.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 22.02
P/E Growth: N/A
Net Income: $-33,260,000.00
Net Margins: -1.95%
Pretax Margin: -3.93%
Return on Equity: 3.84%
Return on Assets: 2.99%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 2.43
Quick Ratio: 1.16

Sales & Book Value

Annual Sales: $1.71 billion
Price / Sales: 1.82
Cash Flow: $6.21 per share
Price / Cash Flow: 9.15
Book Value: $62.66 per share
Price / Book: 0.91

Miscellaneous

Outstanding Shares: 54,840,000
Free Float: 53,524,000
Market Cap: $3.12 billion
Optionable: Optionable
Beta: 1.97

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Matthew L. Trerotola (Age 57)
CEO & Chairman
Comp: $5.12M
Mr. Brady R. Shirley (Age 58)
President, COO & Director
Comp: $3.34M
Ms. Patricia A. Lang (Age 65)
Senior VP & Chief Human Resources Officer
Comp: $1.59M
Mr. Daniel A. Pryor (Age 56)
Executive Vice President of Strategy & Business Development
Comp: $2.08M
Mr. Phillip Benjamin Berry (Age 45)
Senior VP & CFO
Mr. John Kleckner (Age 47)
VP, Controller & Chief Accounting Officer
Derek Leckow
Vice President of Investor Relations
Mr. Bradley J. Tandy (Age 65)
Senior VP & Chief Legal Officer
Katie Sweet
Vice President of Corporate Communication
Mr. Terry Ross (Age 54)
Group President Prevention & Recovery

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ENOV Stock Analysis - Frequently Asked Questions

Should I buy or sell Enovis stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENOV shares.
View ENOV analyst ratings or view top-rated stocks.
What is Enovis' stock price target for 2024?: 8 brokers have issued 12 month price objectives for Enovis' shares. Their ENOV share price targets range from $70.00 to $82.00. On average, they anticipate the company's share price to reach $75.43 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts.
How have ENOV shares performed in 2024?: Enovis' stock was trading at $56.02 at the beginning of 2024. Since then, ENOV shares have increased by 1.4% and is now trading at $56.82.
View the best growth stocks for 2024 here.
When is Enovis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ENOV earnings forecast.
How were Enovis' earnings last quarter?: Enovis Co. (NYSE:ENOV) released its quarterly earnings results on Thursday, February, 22nd. The company reported $0.79 EPS for the quarter, topping analysts' consensus estimates of $0.76 by $0.03. The firm had revenue of $455 million for the quarter, compared to analyst estimates of $444.34 million. Enovis had a negative net margin of 1.95% and a positive trailing twelve-month return on equity of 3.84%. The company's revenue for the quarter was up 11.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.72 earnings per share.

What ETFs hold Enovis' stock?: ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Dimensional US Small Cap Value ETF (DFSV).iShares U.S. Medical Devices ETF (IHI).
What guidance has Enovis issued on next quarter's earnings?: Enovis issued an update on its FY24 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of $2.50-$2.65 for the period, compared to the consensus earnings per share estimate of $2.70. The company issued revenue guidance of $2.05-$2.15 billion, compared to the consensus revenue estimate of $2.02 billion.
Who are Enovis' major shareholders?: Enovis' stock is owned by many different institutional and retail investors. Top institutional investors include Portman Square Capital LLP (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota.
View institutional ownership trends.
How do I buy shares of Enovis?: Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENOV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enovis (ENOV) Stock Price, News & Analysis

Enovis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Enovis Stock (NYSE:ENOV)

ENOV Stock Price History

ENOV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ENOV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™